ONO PHARMACEUTICAL CO., LTD. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2,300 JPY | +1.34% |
|
+2.77% | -8.59% |
| Sales 2024 * | 509B 3.21B | Sales 2025 * | 482B 3.04B | Capitalization | 1,080B 6.82B |
|---|---|---|---|---|---|
| Net income 2024 * | 132B 831M | Net income 2025 * | 110B 697M | EV / Sales 2024 * | 1.82 x |
| Net cash position 2024 * | 157B 992M | Net cash position 2025 * | 220B 1.39B | EV / Sales 2025 * | 1.78 x |
| P/E ratio 2024 * |
8.37
x | P/E ratio 2025 * |
9.92
x | Employees | 3,761 |
| Yield 2024 * |
3.47% | Yield 2025 * |
3.52% | Free-Float | 75.82% |
More Fundamentals
* Assessed data
More news
Latest transcript on Ono Pharmaceutical Co., Ltd.
More recommendations
More press releases
More news
| 1 day | +1.34% | ||
| 1 week | +2.77% | ||
| Current month | -6.29% | ||
| 1 month | -8.06% | ||
| 3 months | -13.44% | ||
| 6 months | -11.79% | ||
| Current year | -8.59% |
1 week
2 241.00
2 318.00
1 month
2 238.002 523.00
Current year
2 238.002 777.00
1 year
2 238.002 966.50
3 years
2 238.003 990.00
5 years
1 822.003 990.00
10 years
1 542.005 880.00
| Managers | Title | Age | Since |
|---|---|---|---|
Gyo Sagara
CEO | Chief Executive Officer | 65 | 83-03-31 |
Toichi Takino
PSD | President | 55 | - |
| Director/Board Member | 64 | 85-03-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Isao Ono
BRD | Director/Board Member | 65 | 81-03-31 |
Shusaku Nagae
BRD | Director/Board Member | 74 | - |
| Director/Board Member | 64 | 85-03-31 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 3.23% | 15 M€ | +7.34% | ||
| 0.67% | 251 M€ | +13.17% |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-26 | 2,300 | +1.34% | 3,191,300 |
| 24-04-25 | 2,270 | -1.09% | 1,863,000 |
| 24-04-24 | 2,294 | +0.17% | 2,300,000 |
| 24-04-23 | 2,290 | -0.09% | 1,838,400 |
| 24-04-22 | 2,292 | +2.44% | 2,350,100 |
Delayed Quote Japan Exchange, April 26, 2024 at 02:00 am EDT
More quotes
ONO PHARMACEUTICAL CO., LTD. is a Japan-based company primarily engaged in the manufacture and sale of pharmaceuticals. The Company operates in one business segment. The Pharmaceutical segment involves in the manufacture and sale of drugs for medical and general use. The Company also involves in the clinical development, introduction and derivation of pharmaceuticals.
Sector
Pharmaceuticals
Calendar
2024-05-08
- Q4 2023 Earnings Release
Trading Rating
Investor Rating
ESG Refinitiv
B+
Sell
Buy
Mean consensus
HOLD
Number of Analysts
12
Last Close Price
2,300
JPY
Average target price
2,656
JPY
Spread / Average Target
+15.47%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -8.59% | 6.85B | |
| +19.62% | 43.78B | |
| +20.44% | 21.89B | |
| +10.86% | 14.45B | |
| +13.07% | 13.63B | |
| +37.46% | 11.49B | |
| -0.05% | 6.79B | |
| -8.87% | 5.73B | |
| +8.46% | 5.06B | |
| -4.29% | 4.66B |
- Stock Market
- Equities
- 4528 Stock
